First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures declines year over year
Q1 FY2026 capital expenditures of $17K (cash outflow) fell 51.4% year over year.
Context
- Capital expenditures grew in size in 0 of the last 2 fiscal years.
- FY2025 was the smallest annual figure in the 3 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (87K) USD
- Year-over-year change
- +75.7%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (87K) | +75.7% |
| FY2024 | 2024-12-31 | (358K) | +55.6% |
| FY2023 | 2023-12-31 | (807K) | — |
Capital Expenditures vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's FY2025 capital expenditures of $87K is the 5th largest of the 10 companies compared; the peer median is $81K.
- Its year-over-year change of -75.7% is the 5th highest of 8, against a peer median of -58.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $4.49M | +2781.2% | -24.5% | — | |
| FY2025 | $2.31M | +30.5% | — | 171.3% | |
CLYMClimb Bio, Inc. | LTM Mar 2026 | $186K | — | — | — |
| LTM Mar 2026 | $116K | -58.6% | +12.9% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $87K | -75.7% | — | — |
| LTM Mar 2026 | $81K | -99.8% | -43.2% | 1.0% | |
| LTM Mar 2026 | $69K | -81.1% | -37.6% | 0.0% | |
| LTM Sep 2026 | $8K | -97.9% | -65.6% | 0.1% | |
| LTM Mar 2026 | $0 | +100.0% | +29.8% | — | |
| LTM Mar 2026 | $0 | — | — | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $81K | -58.6% | -31.0% | 0.5% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (106.15M) | (163.71M) | (166.09M) |
| Depreciation & Amortization | 2.38M | 2.4M | 2.42M |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 18.39M | 26.83M | 32.3M |
| Change in Working Capital | 2.9M | 18.99M | (1.52M) |
| Accounts Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Accounts Payables | 8.39M | 17.81M | 0 |
| Other Working Capital | (5.49M) | 1.18M | (1.52M) |
| Other Non-Cash Items | (10.52M) | (10.31M) | (10.04M) |
| Operating Cash Flow | (93M) | (125.81M) | (142.93M) |
| Capital Expenditures | (807K) | (358K) | (87K) |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | (303.92M) | (380.38M) | 0 |
| Sales of Investments | 449.48M | 476.13M | 0 |
| Other Investing Activities | 0 | 0 | 228.12M |
| Investing Cash Flow | 144.75M | 95.4M | 228.03M |
| Debt Repayment | 0 | 0 | 0 |
| Common Stock Issued | 0 | 117.52M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 30.01M |
| Financing Cash Flow | (87.09M) | 117.52M | 30.01M |
| Effect of Forex Changes | 0 | 0 | 0 |
| Net Change in Cash | (35.34M) | 87.12M | 115.12M |
| Free Cash Flow | (93.81M) | (126.16M) | (143.01M) |
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.